Structural and molecular aspects of betaine-GABA transporter 1 (BGT1) and its relation to brain function. (15th December 2019)

• Record Type: Journal Article
• Authors: Kickinger, Stefanie; Hellsberg, Eva; Frølund, Bente; Schousboe, Arne; Ecker, Gerhard F.; Wellendorph, Petrine
• Is Part Of: Neuropharmacology. Volume 161(2019)
• Publication Date: 2019-12-15
• Subjects: Betaine/γ-aminobutyric acid transporter 1 -- GABA transporter -- Homology modeling -- Molecular docking -- GABA uptake -- SLC6A12; BGT1 Betaine/γ-aminobutyric acid transporter 1 -- BHMT1 betaine-homocysteine S-methyltransferase -- CHO Chinese Hamster Ovary -- CreaT creatine transporter -- GABA Ɣ Aminobutyric acid, GAT GABA transporter -- DAT Dopamine Transporter -- GlyT Glycine Transporter -- HEK human Embryonic Kidney -- h human -- m mouse -- r rat -- SERT Serotonin Transporter -- LeuTAa Leucine Transporter in Aquifexaeolicus -- TauT Taurine Transporter -- NTT Neurotransmitter Transporter -- SLC6 Solute Carrier Transporter family 6; Neuropsychopharmacology -- Periodicals; Autonomic Agents -- Periodicals; Neuropsychopharmacologie -- Périodiques; Neuropsychopharmacology; Periodicals; Electronic journals; 615.78
• DOI: 10.1016/j.neuropharm.2019.05.021
• Languages: English
• ISSNs: 0028-3908

Abstract

Abstract: ɣ-aminobutyric-acid (GABA) functions as the principal inhibitory neurotransmitter in the central nervous system. Imbalances in GABAergic neurotransmission are involved in the pathophysiology of various neurological diseases such as epilepsy, Alzheimer's disease and stroke. GABA transporters (GATs) facilitate the termination of GABAergic signaling by transporting GABA together with sodium and chloride from the synaptic cleft into presynaptic neurons and surrounding glial cells. Four different GATs have been identified that all belong to the solute carrier 6 (SLC6) transporter family: GAT1-3 (SLC6A1, SLC6A13, SLC6A11) and betaine/GABA transporter 1 (BGT1, SLC6A12). BGT1 has emerged as an interesting target for treating epilepsy due to animal studies that reported anticonvulsant effects for the GAT1/BGT1 selective inhibitor EF1502 and the BGT1 selective inhibitor RPC-425. However, the precise involvement of BGT1 in epilepsy remains elusive because of its controversial expression levels in the brain and the lack of highly selective and potent tool compounds. This review gathers the current structural and functional knowledge on BGT1 with emphasis on brain relevance, discusses all available compounds, and tries to shed light on the molecular determinants driving BGT1 selectivity. This article is part of the issue entitled 'Special Issue on Neurotransmitter Transporters'. Graphical abstract: Image 1 Highlights: Structural and molecular details of BGT1 are summarized including known inhibitors. Different accommodation of the ligands' amino moiety contributes to selectivity. The absence of a carboxylic acid moiety may indicate allosteric inhibition. Development of an inhibitor radioligand could facilitate new insights into BGT1. The Na3 binding site represents an interesting topic for future investigations.